Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Author: admin

New article published in a Cypriot Newspaper by members of the Zanos Lab: Understanding “Smiling” Depression in the Era of Social Media

No Comments
| News

Researchers from the Zanos Lab have published an article in the Greek newspaper “Neolaia” (Youth) examining the phenomenon of “smiling” depression. This form of depression is characterized by individuals presenting a cheerful, successful image on social media while concealing their true feelings of sadness. The article, co-authored by Dr. Anna Onisiforou and Dr. Panos Zanos, […]

Read More »

Zanos laboratory’s BioNic research featured in major Cypriot newspaper: Pioneering the future of smoking cessation

No Comments
| News

The Zanos Laboratory at the University of Cyprus has recently been featured in one of Cyprus’ leading newspapers for its groundbreaking BioNic research program. Led by Principal Investigator Dr. Panos Zanos and Marie Curie fellow Dr. Andrea N. Georgiou, this innovative study aims to revolutionize smoking cessation strategies by identifying biological markers that can predict […]

Read More »

Groundbreaking Phase I clinical trial results: (2R,6R)-Hydroxynorketamine (HNK) shows excellent safety profile.

No Comments
| News

We are thrilled to announce a major milestone in our research journey. The manuscript detailing the Phase I clinical trial results for (2R,6R)-Hydroxynorketamine (HNK), a metabolite of ketamine, has just been published. The study, titled “A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-HNK in healthy volunteers,” demonstrates the compound’s excellent […]

Read More »

Dr. Zanos’s Research Leads the Field in Ketamine Studies for Depression

No Comments
| News

We are proud to announce that Dr. Zanos’s groundbreaking research on ketamine has achieved exceptional recognition within the scientific community. According to a recent publication in the European Archives of Psychiatry and Clinical Neuroscience, Dr. Zanos’s work constitutes the top three most cited papers on ketamine and its enantiomers for depression from 2000 to 2023. […]

Read More »

Gut-Brain connections: Dr. Charalambous presents groundbreaking research on phageome and brain ageing at Grainau workshop

No Comments
| News

Our postdoctoral researcher Eleftheria Charalambous presented our latest findings at the 12th Grainau Workshop of Genetic Epidemiology in Grainau, Germany. With her talk “The gut phageome is associated with brain ageing” she sparked insightful conversations with other researchers. Dr. Charalambous studies the link between bacteriophages in the gut microbiome and the brain. Bacteriophages are viruses […]

Read More »

Dr. Zanos was invited as an expert to give an interview and answer critical question about depression and its underlying mechanisms by a groundbreaking European-funded initiative.

No Comments
| News

Dr. Zanos was invited as an expert contributor to the “TO AITION” project’s Q&A section. “TO AITION” is a groundbreaking EU-funded project investigating the complex relationship between cardiovascular disease (CVD) and depression, aiming to uncover underlying mechanisms and develop novel tools for prevention, diagnosis, and treatment. In this role, Dr. Zanos addressed critical questions about […]

Read More »

Dr. Zanos discusses drug addiction on the satellite television channel of the Cyprus Broadcasting Corporation (RIK 1).

No Comments
| News

We are thrilled to share that Dr. Panos Zanos was invited to appear on RIK Sat, the satellite television channel of the Cyprus Broadcasting Corporation (CyBC), to discuss the critical issue of drug addiction. This invitation from RIK Sat, one of Cyprus’s premier broadcasting platforms, underscores the significance of Dr. Zanos’ work in the field […]

Read More »

New Preprint: Network-Based Analysis Identifies Targetable Pathways in Comorbid Type II Diabetes and Neuropsychiatric Disorders.

No Comments
| News

We are pleased to announce the release of a new preprint from Dr. Anna Onisiforou and Dr. Panos Zanos, titled “Network-Based Analysis Identifies Targetable Pathways in Comorbid Type II Diabetes and Neuropsychiatric Disorders.” This preprint is available on bioRxiv and represents a significant step forward in understanding the complex interactions between Type 2 Diabetes Mellitus […]

Read More »

Dr. Zanos Speaks on Neurobiology of Drug Addiction at Substance Use Disorders Awareness Event in Cyprus

No Comments
| News

We are excited to share that Dr. Zanos was invited by OFSEAK Cyprus and the Cyprus Anti-Cancer Society to deliver a keynote address on the neurobiology of drug addiction at a recent Substance Use Disorders Awareness event. This notable event took place in Cyprus and was covered extensively by several television outlets. Dr. Zanos’s presentation […]

Read More »

New Publication: Molecular Signatures of Premature Aging in Major Depression and Substance Use Disorders.

No Comments
| News

We are excited to announce the latest publication from our talented Research Associate and Head of the Bioinformatics Unit, Dr. Anna Onisiforou, in collaboration with Dr. Polymnia Georgiou. Their groundbreaking paper, titled “Molecular signatures of premature aging in Major Depression and Substance Use Disorders,” has been published in Scientific Data (Nature Group). Major depressive disorder (MDD) and […]

Read More »

Posts pagination

Previous 1 … 9 10 11 12 Next

Recent Posts

  • New Publication in Neuroscience & Biobehavioral Reviews: A Hierarchical Framework for Nociplastic Pain September 11, 2026
  • Dr. Charalambous presents brain aging research at AAIC 2026 July 13, 2026
  • Mapping the Epstein-Barr Virus-Multiple Sclerosis Axis: Dr. Anna Onisiforou presents VirTrack and VirTarget at the FENS Forum 2026 July 9, 2026
  • Dr. Panoutsopoulos presents research on ketamine and early neurodevelopment at FENS Forum 2026 July 8, 2026
  • Research spotlight: Unraveling the role of Eukaryotic Elongation Factor 2 Kinase in the antidepressant mechanism of (2R,6R)-hydroxynorketamine June 4, 2026

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2026 . Powered by WordPress